PRODUCT
Servier Acquires Rights to Black Diamond’s Solid Tumor Drug BDTX-4933 in $780M Deal
Servier, Black Diamond Therapeutics, BDTX-4933, solid tumors, licensing agreement, RAS/RAF inhibitor
Curevo Secures $110M for Advanced Shingles Vaccine Development
Curevo Vaccine, amezosvatein, shingles vaccine, Series B funding, improved tolerability, Shingrix competitor
Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout
Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense
Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market
Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms
Carvykti, Johnson and Johnson, Investments, J&J, Facility (object), Multiple Myeloma, production, competition
Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate
Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist
FDA Approves First Treatment for Macular Telangiectasia Type 2 (MacTel)
ENCELTO, revakinagene taroretcel-lwey, MacTel, FDA approval, encapsulated cell therapy, ciliary neurotrophic factor (CNTF)
Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger
Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction
BioCity’s SC0062 Shows Promise in Phase 2 Trial for Diabetic Kidney Disease
SC0062, endothelin receptor type A (ETA) antagonist, diabetic kidney disease (DKD), proteinuria reduction, phase 2 trial, BioCity Biopharma
Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans
Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A